Document Detail


Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
MedLine Citation:
PMID:  17338931     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The recognition that endothelin-1 contributes to the pathogenesis of pulmonary arterial hypertension has led to the development of clinically useful endothelin receptor antagonists that improve symptoms and functional capacity and alter the natural history of the disease in a beneficial way. The antagonists have varying degrees of selectivity for the two classes of endothelin receptor, termed ETA and ETB, and the varying degrees may translate into clinical differences. Endothelin receptor antagonists have become an integral part of therapy for pulmonary arterial hypertension, and the indications for their use are expanding.
Authors:
David Langleben
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinics in chest medicine     Volume:  28     ISSN:  0272-5231     ISO Abbreviation:  Clin. Chest Med.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-06     Completed Date:  2007-05-15     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  7907612     Medline TA:  Clin Chest Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  117-25, viii     Citation Subset:  IM    
Affiliation:
McGill University, Montreal, Quebec, Canada. david.langleben@mcgill.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use
Drug Therapy, Combination
Humans
Hypertension, Pulmonary / drug therapy*
Isoxazoles / therapeutic use
Phenylpropionates / therapeutic use
Pyridazines / therapeutic use
Randomized Controlled Trials as Topic
Receptors, Endothelin / antagonists & inhibitors*
Sulfonamides / therapeutic use
Thiophenes / therapeutic use
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Isoxazoles; 0/Phenylpropionates; 0/Pyridazines; 0/Receptors, Endothelin; 0/Sulfonamides; 0/Thiophenes; 0/sitaxsentan; 177036-94-1/ambrisentan; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Standard therapies for pulmonary arterial hypertension.
Next Document:  Prostanoid therapy for pulmonary arterial hypertension.